2-Thiazoline → HCID 58614818, compound

HRID 1364687Notes

Reaction equation

HRID 1364687 reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:8]=[CH:9][C:10]=1[C:11](=[O:26])[NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)[C:5]([OH:7])=O.[S:27]1[CH2:31][CH2:30][N:29]=[CH:28]1>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]([N:29]2[CH2:30][CH2:31][S:27][CH2:28]2)=[O:7])[CH:8]=[CH:9][C:10]=1[C:11]([NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)=[O:26]

Participants

3

Reactant 2

HCID 1202692-ThiazolineHCID 668786053-Chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid

Product 1

HCID 58614818HCID 58614818, compound

Procedure

50 mg of 3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to thiazoline via Procedure G. The product was purified on reverse phase HPLC to yield 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(thiazolidine-3-carbonyl)benzamide. MS (Q1) 459 (M)+.

Workup

  1. customThe product was purified on reverse phase HPLC

Sources & evidence

ORD record
ord-af232be1d32049cabce65236a4627882
Source dataset
uspto-grants-2011_02
Patent number
US07888364B2

Reaction notes

Loading…